AB Science

A8D

Company Profile

  • Business description

    AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.

  • Contact

    3, Avenue George V
    Paris75008
    FRA

    T: +33 147200014

    https://www.ab-science.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    33

Stocks News & Analysis

stocks

Nvidia earnings: Business as usual as forecasts suggest that all is well

Are the shares cheap?
stocks

Why don’t good returns guarantee a 5-star rating?

Amy Arnott explains how Morningstar’s stock ratings work.
stocks

Despite post earnings rally ASX share still cheap

Lifting our 2028 earnings estimate by 20%.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,932.4064.90-0.72%
CAC 408,198.3018.48-0.22%
DAX 4025,964.0981.28-0.31%
Dow JONES (US)50,759.42848.75-1.64%
FTSE 10010,637.1152.76-0.49%
HKSE23,294.75213.42-0.91%
NASDAQ24,328.38181.38-0.74%
Nikkei 22559,024.28163.850.28%
NZX 50 Index14,264.2942.67-0.30%
S&P 5007,340.5376.06-1.03%
S&P/ASX 2008,821.8061.40-0.69%
SSE Composite Index3,587.833.250.09%

Market Movers